Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (TYNERGY)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT00884481
First received: April 17, 2009
Last updated: July 9, 2015
Last verified: July 2015

April 17, 2009
July 9, 2015
March 2009
June 2011   (final data collection date for primary outcome measure)
To investigate the MS related fatigue during treatment with Tysabri as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of 12 months. [ Time Frame: 0 month and 12 months ] [ Designated as safety issue: No ]
A fatigue scale for motor and cognitive functions (FSMC) has been developed and validated by Penner et al. FSMC differentiates between motor and cognitive fatigue and is less susceptible to confounding by depression. Thus, FSMC is more specific in measuring MS-related fatigue.
To investigate the MS related fatigue during treatment with TYSABRI as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of 12 months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00884481 on ClinicalTrials.gov Archive Site
  • Changes in fatigue after initiation of Tysabri treatment [ Time Frame: 3 months, 6 months, 9 months ] [ Designated as safety issue: No ]
  • Change in capacity for work (capacity for work questionnaire (CWQ)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    Capacity for Work Questionnaire (CWQ) is used to collect data regarding number of working hours and sickness absence.
  • Change in health-related-quality of life (HRQ0L) (short form-12 questions (SF-12)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall HRQOL. Physical and Mental Health Composite Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health.
  • Change in Sleepiness (Epworth sleepiness scale (ESS)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    The ESS is a self-administered 8-item questionnaire with that provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. Each question is rated on a 4-point scale (0 - 3), their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily lives, although not necessarily every day. The total ESS score is the sum of 8 item-scores and can range between 0 and 24, where higher scores indicate higher levels of a person's level of daytime sleepiness.
  • Change in cognitive impairment (the paced auditory serial addition test (PASAT) and symbol digit modalities test (SDMT)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. The PASAT is the third and last component of the MSFC. SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).
  • Change in depression (Center for epidemiologic studies depression scale (CES-D)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    CES-D is a self-report measure of depression severity.
  • Change in Physical activity induced exhaustion (Borg scale CR10 (BS-CR10)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    The Borg Scale measures perceived exertion. It is used to document the patient's exertion during a test. It ranges from 6 to 20, where 6 means "no exertion at all" and 20 means "maximal exertion.
  • Change in speed of walking (6MWT) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
  • Change in status of MS disease progression (expanded disability status scale (EDSS)) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
    The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
  • Change in amount of walking (step counter) at different points after initiation of Tysabri treatment [ Time Frame: 0, 6 months, 12 months ] [ Designated as safety issue: No ]
  • To investigate correlation between fatigue and cognitive impairment, depression and physically activity induced exhaustion and status of MS disease progression [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
  • To document any changes in fatigue related medication [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Changes in fatigue, capacity for work, HRQoL, sleepiness, cognitive impairment, physical activity induced exhaustion, speed of walking, status of MS disease progression and amount of walking at different time points after initiation of TYSABRI treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • To investigate correlation between fatigue and cognitive impairment, depression and physically activity induced exhaustion and status of MS disease progression [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • To document any changes in fatigue related medication [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months

The primary objective of this trial is to observe the Multiple Sclerosis (MS) related fatigue during treatment with Tysabri as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of 12 months. The secondary objectives are: To investigate changes in fatigue, capacity for work, Health Related Quality of Life (HRQol), sleepiness, cognitive impairment, physically activity induced exhaustion, speed of walking, status of MS disease progression and amount of walking at different times points after initiation of Tysabri treatment in participants diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS). Changes in fatigue are measured at 3, 6 and 9 months, whereas changes in capacity for work, HRQoL, sleepiness, cognitive impairment, physical activity induced exhaustion, speed of walking, status of MS disease progression and amount of walking are measured at 6 and 12 months. To investigate correlation between fatigue and cognitive impairment, depression and physically activity induced exhaustion and status of MS disease progression in participants at baseline, 6 and 12 month of treatment with Tysabri and to document any changes in fatigue related medication.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Subjects diagnosed with Relapsing Remitting Multiple Sclerosis initiating treatment with Tysabri

  • Relapsing-Remitting Multiple Sclerosis
  • Fatigue
Other: Natalizumab
Participants treated with Tysabri
Other Names:
  • BG00002
  • Tysabri
Natalizumab
Participants with MS treated with Tysabri over 12 months
Intervention: Other: Natalizumab
Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berkö S, Sun J, Penner IK; Tynergy Trial Investigators. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One. 2013;8(3):e58643. doi: 10.1371/journal.pone.0058643. Epub 2013 Mar 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
June 2011
June 2011   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Tysabri prescribed according to national guidelines but not yet started treatment
  • Signed informed consent form
  • FSMC sum score above > 43 at baseline (mild fatigue)

Key Exclusion Criteria:

  • FSMC sum score below 43 at baseline
  • History of treatment with Tysabri
  • EDSS > 6 at baseline
  • Amphetamine as medication
  • Major depression

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
Sweden,   Norway
 
NCT00884481
2008-008065-35
No
Biogen
Biogen
Not Provided
Study Director: Medical Director Biogen
Biogen
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP